💊#FDA Approval Update | #Sotyktu (#deucravacitinib): a #TYK-targeting therapy for adults with active #PsA
➡️To manage #skin & #joint symptoms
✅Significant #ACR20 responses in Phase 3 POETYK PsA-1 and PsA-2 trials
#PsoriaticArthritis #Autoimmune #AutoimmuneDisease